Want to see RZLT full AI Analyst Report?
Top Page
Rezolute
(NASDAQ:RZLT)
Select Model
Select Model
Rating:56Neutral
Price Target:
$5.00
▼(-0.20% Downside)
Action:Reiterated
Date:06/04/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and increasing cash burn), partly offset by a low-debt balance sheet. Technicals are constructive but overbought, and recent positive Phase 3 and FDA-interaction updates improve the outlook despite valuation being constrained by losses.
Positive Factors
Low leverage / conservative balance sheet
Very low debt reduces near-term refinancing risk and gives strategic financial flexibility to prioritize R&D or partnerships. For a development-stage biotech, minimal leverage lowers fixed obligations and preserves options to time future financings or collaborations.
Negative Factors
Accelerating cash burn
Substantially negative and worsening free cash flow indicates heavy ongoing cash consumption to fund trials. Over 2–6 months this increases the probability management must raise capital, which can dilute shareholders and constrain discretionary investment in pipeline expansion or commercialization readiness.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / conservative balance sheet
Very low debt reduces near-term refinancing risk and gives strategic financial flexibility to prioritize R&D or partnerships. For a development-stage biotech, minimal leverage lowers fixed obligations and preserves options to time future financings or collaborations.
Read all positive factors
Rezolute (RZLT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$441.02M
Dividend YieldN/A
Average Volume (3M)1.26M
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue GrowthN/A
EPS Growth29.97%
CountryUS
Employees68
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.82
Shares Outstanding96,292,330
10 Day Avg. Volume1,044,894
30 Day Avg. Volume1,256,727
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.33Price Target Upside46.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$2.88M
Rezolute Business Overview & Revenue Model
Company Description
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal...
How the Company Makes Money
Rezolute is a clinical-stage biotechnology company, and detailed, consistent product-revenue information is not available because it does not appear to have a widely disclosed commercial product generating recurring sales. As a result, its operati...
Rezolute Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -23.00K | 0.00 | 0.00 | 0.00 | 0.00 | -13.00K |
| EBITDA | -81.45M | -74.38M | -68.42M | -51.76M | -39.24M | -20.51M |
| Net Income | -81.48M | -74.41M | -68.46M | -51.79M | -41.06M | -20.90M |
Balance Sheet | ||||||
| Total Assets | 125.46M | 175.49M | 132.74M | 123.72M | 152.42M | 42.61M |
| Cash, Cash Equivalents and Short-Term Investments | 120.27M | 167.86M | 126.87M | 101.90M | 150.41M | 41.05M |
| Total Debt | 1.11M | 1.61M | 2.23M | 2.48M | 188.00K | 14.42M |
| Total Liabilities | 8.63M | 13.36M | 11.73M | 7.55M | 2.95M | 16.51M |
| Stockholders Equity | 116.83M | 162.13M | 121.00M | 116.17M | 149.47M | 26.10M |
Cash Flow | ||||||
| Free Cash Flow | -73.48M | -69.08M | -57.37M | -44.63M | -39.62M | -20.44M |
| Operating Cash Flow | -73.48M | -69.08M | -57.37M | -44.48M | -39.62M | -20.44M |
| Investing Cash Flow | -33.05M | -14.54M | 48.70M | -101.46M | 0.00 | 0.00 |
| Financing Cash Flow | 103.17M | 107.33M | 63.03M | 11.57M | 148.98M | 51.53M |
Rezolute Technical Analysis
Neutral
5.01
Price Trends
4.81
Negative
4.25
Positive
4.13
Positive
Market Momentum
-0.04
Positive
44.77
Neutral
14.57
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RZLT, the sentiment is Neutral. The current price of 5.01 is above the 20-day moving average (MA) of 4.73, above the 50-day MA of 4.81, and above the 200-day MA of 4.13, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 44.77 is Neutral, neither overbought nor oversold. The STOCH value of 14.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RZLT.
Rezolute Risk Analysis
Rezolute disclosed 31 risk factors in its most recent earnings report. Rezolute reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rezolute Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.02B | 6.51 | 90.98% | ― | 1078.78% | ― | |
56 Neutral | $441.02M | -5.59 | -58.82% | ― | ― | 29.97% | |
56 Neutral | $1.01B | -15.75 | -30.31% | ― | 24.39% | 21.06% | |
55 Neutral | $1.82B | -13.25 | -56.19% | ― | -32.27% | -21.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.98B | -12.26 | -28.66% | ― | -28.56% | 10.25% | |
47 Neutral | $2.22B | -8.44 | -273.23% | ― | ― | -10.60% |
* Healthcare Sector Average
RZLT
Rezolute
4.58
-3.37
-42.39%
GERN
Geron
1.57
0.20
14.60%
ABUS
Arbutus Biopharma
5.15
1.06
25.92%
XNCR
Xencor
26.61
18.20
216.41%
KOD
Kodiak Sciences
35.36
25.57
261.18%
TSHA
Taysha Gene Therapies
5.60
2.36
72.84%
Rezolute Corporate Events
Business Operations and StrategyProduct-Related Announcements
Rezolute Reports Positive Phase 3 Data for Ersodetug
Positive
Jun 2, 2026
On June 2, 2026, Rezolute reported positive interim data from its open-label Phase 3 upLIFT trial evaluating ersodetug in tumor hyperinsulinism, a rare and severe cause of hypoglycemia linked to insulinoma and non-islet cell tumors. The company ha...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Rezolute Shares Expanded Phase 3 sunRIZE Data With FDA
Positive
May 4, 2026
On May 1, 2026, Rezolute announced expanded Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism, presented at the Pediatric Endocrine Society 2026 meeting, showing consistent, clinically meaningful improvements in continuous glucose m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.